Anti-rabies monoclonal antibody (Rabimabs) - Zydus Cadila

Drug Profile

Anti-rabies monoclonal antibody (Rabimabs) - Zydus Cadila

Alternative Names: Anti-rabies monoclonal antibody - Zydus Cadila; Anti-rabies monoclonal antibody cocktail - Zydus Cadila; M777-16-3/MAb 62-71-3; MAB 5; Rabies mAb - Zydus Cadila/WHO; Rabimabs

Latest Information Update: 14 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zydus Cadila
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rabies

Most Recent Events

  • 01 Aug 2017 Phase-III clinical trials in Rabies in India (IM) (CTRI2017-07-009038)
  • 21 Mar 2016 Cadila completes a phase I/II trial in Rabies in India (IM) (CTRI 2015-06-005838)
  • 21 Jan 2016 Phase-I/II clinical trials in Rabies in India (IM) (CTRI2015-06-005838)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top